Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
361 questions in 74 reviews · Pain, Palliative and Supportive Care
current versionsNo studies 361 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Topical clonidine (TC) vs active comparator Withdrawals due to adverse events during longest · adults with painful diabetic neuropathy Topical clonidine for neuropathic pain in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Topical clonidine (TC) vs active comparator Participants experiencing at least 1adverse event during longest · adults with painful diabetic neuropathy Topical clonidine for neuropathic pain in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Topical clonidine (TC) vs active comparator Withdrawal due to lack of efficacy (12 weeks) · adults with painful diabetic neuropathy Topical clonidine for neuropathic pain in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Topical clonidine (TC) vs active comparator Participant‐reported pain relief of 30% or greater during longest · adults with painful diabetic neuropathy Topical clonidine for neuropathic pain in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic dopamine antagonist antiemetic medications vs placebo Number of vomiting episodes · adults receiving intravenous opioids Prophylactic antiemetics for adults receiving intravenous opioids in the acute care setting (2022) · Cochrane | no estimate extracted | NR | No studies |
Exercise plus usual care vs usual care Muscle strength and endurance · cancer cachexia in adults Exercise for cancer cachexia in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
Exercise plus usual care vs usual care Maximal and submaximal exercise capacity Functional capacity · cancer cachexia in adults Exercise for cancer cachexia in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
Multimodal intervention (exercise plus other interventions) plus usual care vs usual care Adherence to prescribed exercise programmes · cancer cachexia in adults Exercise for cancer cachexia in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
Hydromorphone vs morphine Quality of life · people with moderate to severe cancer pain Hydromorphone for cancer pain (2021) · Cochrane | no estimate extracted | NR | No studies |
Hydromorphone vs fentanyl Participant‐reported pain relief · people with moderate to severe cancer pain Hydromorphone for cancer pain (2021) · Cochrane | no estimate extracted | NR | No studies |
Hydromorphone vs fentanyl Specific adverse events – nausea · people with moderate to severe cancer pain Hydromorphone for cancer pain (2021) · Cochrane | no estimate extracted | NR | No studies |
Hydromorphone vs fentanyl Specific adverse events – vomiting · people with moderate to severe cancer pain Hydromorphone for cancer pain (2021) · Cochrane | no estimate extracted | NR | No studies |
Hydromorphone vs fentanyl Specific adverse events – dizziness · people with moderate to severe cancer pain Hydromorphone for cancer pain (2021) · Cochrane | no estimate extracted | NR | No studies |
Hydromorphone vs oxycodone Participant‐reported pain relief · people with moderate to severe cancer pain Hydromorphone for cancer pain (2021) · Cochrane | no estimate extracted | NR | No studies |
Hydromorphone vs fentanyl Specific adverse events – constipation · people with moderate to severe cancer pain Hydromorphone for cancer pain (2021) · Cochrane | no estimate extracted | NR | No studies |
Hydromorphone vs fentanyl Quality of life · people with moderate to severe cancer pain Hydromorphone for cancer pain (2021) · Cochrane | no estimate extracted | NR | No studies |
Hydromorphone vs oxycodone Quality of life · people with moderate to severe cancer pain Hydromorphone for cancer pain (2021) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron Interventions (corticosteroids included in all regimens)a · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic… (2021) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron Interventions (corticosteroids included in all regimens)a · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic… (2021) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron Interventions (corticosteroids included in all regimens)a · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic… (2021) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: serious adverse events (MEC) when vs treatment with granisetron Interventions (corticosteroids included in all regimens)a · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic… (2021) · Cochrane | no estimate extracted | NR | No studies |
Summary of Findings Table ‐ Ibuprofen vs Placebo Number of participants using rescue medication over a 4‐hour period and over a 6‐hour period postintervention ‐ not reported · health problem or population Single‐dose intravenous ibuprofen for acute postoperative pain in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
Summary of Findings Table ‐ Ibuprofen 300 mg vs active comparator (acetaminophen) Number of participants using rescue medication over a 4‐hour period and over a 6‐hour period postintervention ‐ not reported · health problem or population Single‐dose intravenous ibuprofen for acute postoperative pain in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
Active stimulation vs placebo (sham) Adverse events: Lead failure/ displacement · adults with chronic pain Implanted spinal neuromodulation interventions for chronic pain in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
Active stimulation vs placebo (sham) Adverse events: Need for reoperation/ reimplantation · adults with chronic pain Implanted spinal neuromodulation interventions for chronic pain in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
Active stimulation vs placebo (sham) Pain intensity, continuous outcomes (VAS 0 ‐ 100) · adults with chronic pain Implanted spinal neuromodulation interventions for chronic pain in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
Active stimulation vs placebo (sham) Adverse events: Need for reoperation/reimplantation · adults with chronic pain Implanted spinal neuromodulation interventions for chronic pain in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
Active stimulation + other intervention vs other intervention alone Adverse event: lead failure/ displacement · adults with chronic pain Implanted spinal neuromodulation interventions for chronic pain in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
Active stimulation + other intervention vs other intervention alone Adverse events: infection · adults with chronic pain Implanted spinal neuromodulation interventions for chronic pain in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
Active stimulation + other intervention vs other intervention alone Adverse events: need for reoperation/ reimplantation · adults with chronic pain Implanted spinal neuromodulation interventions for chronic pain in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
Active stimulation + other intervention vs other intervention alone Adverse events: other · adults with chronic pain Implanted spinal neuromodulation interventions for chronic pain in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
Active stimulation vs placebo (sham) Pain intensity. Proportion with ≥ 50% pain relief. · adults with chronic pain Implanted spinal neuromodulation interventions for chronic pain in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
Active stimulation vs placebo (sham) Adverse event: lead failure/ displacement · adults with chronic pain Implanted spinal neuromodulation interventions for chronic pain in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
Active stimulation vs placebo (sham) Adverse events: infection · adults with chronic pain Implanted spinal neuromodulation interventions for chronic pain in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
Active stimulation vs placebo (sham) Adverse events: need for reoperation/ reimplantation · adults with chronic pain Implanted spinal neuromodulation interventions for chronic pain in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
Active stimulation vs placebo (sham) Adverse events: other · adults with chronic pain Implanted spinal neuromodulation interventions for chronic pain in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
Active stimulation vs placebo (sham) Pain intensity, continuous outcomes(VAS 0 ‐ 100) · adults with chronic pain Implanted spinal neuromodulation interventions for chronic pain in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
Active stimulation vs placebo (sham) Pain intensity. Proportion with ≥50% pain relief. · adults with chronic pain Implanted spinal neuromodulation interventions for chronic pain in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
Active stimulation vs placebo (sham) Adverse events: Infection · adults with chronic pain Implanted spinal neuromodulation interventions for chronic pain in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR N/A: Not applicable · Patients with COVID‐19 Interventions for palliative symptom control in COVID‐19 patients (2021) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: haloperidol vs risperidone Adverse events including extrapyramidal effects · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: haloperidol vs olanzapine Agitation within 24 hours · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: haloperidol vs olanzapine Agitation between 24 and 48 hours · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: haloperidol vs olanzapine Adverse events including extrapyramidal effects · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: risperidone vs placebo Agitation within 24 hoursc · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: lorazepam plus haloperidol vs placebo plus haloperidol Symptoms of delirium between 24 and 48 hours · terminally ill adults with severe delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: lorazepam plus haloperidol vs placebo plus haloperidol Agitation between 24 and 48 hoursc · terminally ill adults with severe delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: haloperidol vs chlorpromazine Symptoms of delirium within 24 hours · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: haloperidol vs chlorpromazine Agitation within 24 hours · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: haloperidol vs chlorpromazine Agitation between 24 and 48 hours · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | no estimate extracted | NR | No studies |